INS and Alzheimer disease: Recent studies have shown that a decline in brain glucose metabolism and central insulin resistance are considered characteristic features of metabolic disruption in AD patients (3) Disrupted brain glucose metabolism is a persistent feature throughout the pathological process of AD (5), and it may be a key factor in the disease’s mechanisms, triggering a cascade of reactions leading to neuronal degeneration and cognitive impairment in AD patients.